Nabriva Therapeutics AG (NASDAQ:NBRV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The firm currently has a $12.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 22.70% from the company’s current price.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

NBRV has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating on shares of Nabriva Therapeutics AG in a research report on Friday, May 12th. Cantor Fitzgerald set a $16.00 target price on Nabriva Therapeutics AG and gave the stock a “buy” rating in a research report on Monday, June 5th. Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a research report on Monday, May 15th. Finally, ValuEngine upgraded Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Nabriva Therapeutics AG has a consensus rating of “Buy” and an average target price of $15.43.

Nabriva Therapeutics AG (NASDAQ NBRV) opened at 9.78 on Thursday. The stock has a 50 day moving average price of $10.31 and a 200-day moving average price of $10.27. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75. The firm’s market capitalization is $26.61 million.

Nabriva Therapeutics AG (NASDAQ:NBRV) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million. On average, analysts predict that Nabriva Therapeutics AG will post ($2.43) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Nabriva Therapeutics AG (NASDAQ:NBRV) Upgraded to Buy by Zacks Investment Research” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/nabriva-therapeutics-ag-nasdaqnbrv-upgraded-to-buy-by-zacks-investment-research.html.

In related news, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of the company’s stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $10.96, for a total value of $93,795.68. Following the sale, the insider now owns 2,591,396 shares in the company, valued at approximately $28,401,700.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director George Harrison Talbot sold 325 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $100.56, for a total value of $32,682.00. Following the completion of the sale, the director now owns 3,854 shares in the company, valued at approximately $387,558.24. The disclosure for this sale can be found here. Insiders have sold a total of 242,708 shares of company stock worth $2,646,784 in the last quarter.

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new stake in Nabriva Therapeutics AG during the fourth quarter worth $103,000. Almanack Investment Partners LLC. purchased a new stake in Nabriva Therapeutics AG during the first quarter worth $1,870,000. Nationwide Fund Advisors purchased a new stake in Nabriva Therapeutics AG during the first quarter worth $2,074,000. Finally, Wellington Management Group LLP boosted its stake in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares in the last quarter. Institutional investors and hedge funds own 56.65% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.